MedPath

Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV

Phase 3
Terminated
Conditions
Hepatitis B
Registration Number
NCT00313287
Lead Sponsor
Bukwang Pharmaceutical
Brief Summary

The purpose of this study is to determine safety and efficacy of 30 mg daily dose of clevudine (L-FMAU) at 24 weeks of treatment in patients with chronic HBV.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
180
Inclusion Criteria
  1. Patients who were between 18 and 60, inclusive.
  2. Patients with HBV DNA ³1 x 106 copies/mL within 30 days of baseline.
  3. Patients who were documented to be HBsAg positive for > 6 months. (The documentation of positive HBsAg for the previous 6 months included previous laboratory reports of HBsAg positive or HBeAg positive at least 6 month ago or IgM anti-HBc negative and IgG anti-HBc positive at screening).
  4. Patients who were HBeAg positive.
  5. Patients with ALT levels which were in the range of ≥1.2 and < 15 times of the upper limit of normal (x ULN) and bilirubin levels less than 2.0 mg/dL, prothrombin time of less than 1.7 (INR), and a serum albumin level of at least 3.5 g/dL.
  6. Women of child bearing potential with a negative serum (β-HCG) pregnancy test taken within 14 days of starting therapy.
  7. Patients who were able to give written informed consent prior to study start and to comply with the study requirements.
Exclusion Criteria
  1. Patients who were currently receiving antiviral, immunomodulatory or corticosteroid therapy.

  2. Patients previously treated with lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection.

  3. Previous treatment with interferon that had ended less than 6 months prior to the screening visit.

  4. Patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy.

  5. Patients co-infected with HCV, HDV or HIV.

  6. Patients with clinical evidence of liver mass or with alpha-fetoprotein > 50 ng/mL

  7. Patients who were pregnant or breast-feeding.

  8. Patients who were unwilling to use an "effective" method of contraception during the treatment and for up to 3 months after cessation of therapy. For males, condoms should be used. Females had to be surgically sterile (via hysterectomy or bilateral tubal ligation) or post-menopausal or using at least medically acceptable barrier method of contraception ( i.e. IUD, barrier methods with spermicide or abstinence)

  9. Patients with a clinically relevant history of abuse of alcohol or drugs.

  10. Patients with a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, biliary diseases except asymptomatic GB stone, neurological, cardiovascular, oncologic or allergic disease.

    The patients with a benign tumor were excluded if judged by an investigator that the continuation of study would be interfered by benign tumor.

  11. Patients with creatinine clearance less than 60mL/min as estimated by the following formula :

(140-age in years) (body weight [kg]) (72) (serum creatinine [mg/dL]) [Note: multiply estimates by 0.85 for women]

Patients who were found to have YMDD HBV DNA polymerase mutation at baseline were to be excluded from the overall efficacy evaluation and analyzed separately. They were to be included in the overall safety evaluation.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Efficacy:change from baseline in HBV DNA (log10) at Week 24
Safety: clinically measured adverse events, abnormality of laboratory tests and abnormality of vital signs.
Secondary Outcome Measures
NameTimeMethod
Efficacy:
Proportion of patients with HBV DNA below the assay Limit of Detection
Proportion of patients with HBeAg loss and/or seroconversion (HBeAg loss and HBeAb gain)
Proportion of ALT normalization

Trial Locations

Locations (33)

St. Mercy's Hospital

🇰🇷

Bupyoung-dong, Bupyoung-gu, Incheon, Korea, Republic of

Chonnam National University Hospital

🇰🇷

Hak-1-dong, Dong-gu, Gwangju-si, Korea, Republic of

Kangbuk Samsung Hospital

🇰🇷

Pyoung-dong, Chongro-gu, Seoul, Korea, Republic of

Keimyumg University Dongsan Medical Center

🇰🇷

Jung-gu, Daegu, Korea, Republic of

Korea University Guro Hospital

🇰🇷

Seoul, Gro-gu, Korea, Republic of

Wonkwang University Hospital

🇰🇷

Iksan-City, Jeonbuk, Korea, Republic of

Chonbuk National University Hospital

🇰🇷

Jeonju-city, Jeonbuk, Korea, Republic of

Chungnam National University Hospital

🇰🇷

Daesa-dong, Jung-gu, Daechon, Korea, Republic of

Inha University Hospital

🇰🇷

Sinhung-dong, Jung-gu, Incheon, Korea, Republic of

Yongdong Severance Hospital

🇰🇷

Dogok-dong, Kangnam-gu, Seoul, Korea, Republic of

Seoul Asan Medical Center

🇰🇷

Pungnap-dong, Kangnam-gu, Seoul, Korea, Republic of

National Cancer Center

🇰🇷

Ilsan-gu,, Kyounggi-do, Korea, Republic of

St. Holly Family Mary's Hospital

🇰🇷

Pucheon, Kyounggi-do, Korea, Republic of

Pochon CHA University Hospital

🇰🇷

Seongnam-gu, Kyounggi-do, Korea, Republic of

Yeungnam University Medical Center

🇰🇷

Dae myoung-dong, Nam-gu, Taegu, Korea, Republic of

Korea Cancer Center Hospital

🇰🇷

Gongneung-dong, Nowon-gu, Seoul, Korea, Republic of

St. Vincent's Hospital

🇰🇷

Ji-dong,, Paldal-gu, Suwon, Korea, Republic of

Nowon Eulji Hospital

🇰🇷

Hagye 1-dong, Nowon-gu, Seoul, Korea, Republic of

Pusan Paik Hospital

🇰🇷

Gaegeum-dong, Pusan, Korea, Republic of

Kosin Medical Center

🇰🇷

Amnam-dong, Seo-gu, Pusan, Korea, Republic of

Pusan National University Hospital

🇰🇷

Ami-dong, Seo-gu, Pusan, Korea, Republic of

KangNam St. Mary's Hospital

🇰🇷

Banpo-dong, Seocho-gu, Seoul, Korea, Republic of

Severance Hospital

🇰🇷

Shinchon- dong, Seodaemun-gu, Seoul, Korea, Republic of

Seoul Paik Hospital

🇰🇷

Jeo-dong, Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Ilwon-dong, Songpa-gu, Seoul, Korea, Republic of

Kyungpook National University Medical Hospital

🇰🇷

Jung-gu, Daegu, Korea, Republic of

Ehwa Womans University Mokdong Hospital

🇰🇷

Mok-dong, Yangcheon-gu, Seoul, Korea, Republic of

Korea University Anam Hospital

🇰🇷

Anam-dong, Sungbuk-ku, Seoul, Korea, Republic of

Kangnam Sacred Heart Hospital

🇰🇷

Daelim-dong, Yongdeungpo-gu, Seoul, Korea, Republic of

Soon Chun Hyang University Hospital

🇰🇷

Hannam-dong, Yongsan-gu, Seoul, Korea, Republic of

Gil Medical Center

🇰🇷

Incheon, Korea, Republic of

St. Mary's Hospital

🇰🇷

Seoul, Yungdungpo-Gu, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath